MORE►
Catalyze Dallas Holdings
L to R: Almaden Genomics CEO David Gascoigne, Executive Chairperson Tricia D'Cruz, and Chief Scientific Officer Mark Kunitomi. [Photos: Almaden Genomics]
Three Months After Launching With Its g.nome Platform, Almaden Genomics Names CEO
by David Seeley | Jan 30, 2023
Life sciences industry veteran David Gascoigne will lead the new startup, which was launched in October by Catalyze Dallas Holdings.
Almaden's g.nome cloud-native platform offers "an advanced visual drag-and-drop workflow builder" and curated library of toolkits that can speed bioinformatic pipeline building "from what previously has taken months to mere hours," the company says.
by Kevin Cummings |
Oct 25, 2022
The Dallas-based venture development firm—which specializes in the commercialization of technology it acquires from Fortune 100 companies—has launched Almaden Genomics, a company with a newly released platform designed to streamline genomic workflows. Formerly part of IBM Research before its acquisition by Catalyze Dallas, Almaden calls its g.nome platform "a revolutionary approach to bioinformatics."
“The possibilities for the healthcare innovation it can power are as vast as they are life-changing," says Mark Kunitomi, Almaden's chief scientific officer.
MORE►
